Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension
Chen, Yuefeng
Dan, Kazuhiro
Khalid, Nauman
Rogers, Toby
Shlofmitz, Evan
Torguson, Rebecca
Waksman, Ron
Weintraub, William S
text
xx
2019
monographic
en
Available in print through MWHC library: 2002 - present
English
*Autonomic Denervation/is [Instrumentation]
*Blood Pressure
*Catheter Ablation/is [Instrumentation]
*Device Approval
*Hypertension/th [Therapy]
*Kidney/bs [Blood Supply]
*Renal Artery/ir [Innervation]
*United States Food and Drug Administration
Antihypertensive Agents/tu [Therapeutic Use]
Autonomic Denervation/ae [Adverse Effects]
Blood Pressure/de [Drug Effects]
Catheter Ablation/ae [Adverse Effects]
Drug Resistance
Equipment Design
Equipment Safety
Humans
Hypertension/di [Diagnosis]
Hypertension/pp [Physiopathology]
Patient Safety
Risk Assessment
Risk Factors
Treatment Outcome
United States
MedStar Heart & Vascular Institute
1878-0938
https://dx.doi.org/10.1016/j.carrev.2019.07.016
https://dx.doi.org/10.1016/j.carrev.2019.07.016
Ovid MEDLINE(R)
191010